Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 2,842 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

Zero-preserving imputation of single-cell RNA-seq data

Featured RNA-Seq Job – Computational Scientist

Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies

iDIRECT – disentangling direct from indirect relationships in association networks

small RNA sequencing suggests BPA exposure of the placenta could affect fetal brain development

A comprehensive comparison of supervised and unsupervised methods for cell type identification in single-cell RNA-seq

Using synthetic chromosome controls to evaluate the sequencing of difficult regions within the human genome